Search

Now showing items 1-10 of 19

Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-kappa B activation

Wu, D; Cerutti, C; Lopez-Ramirez, MA; Pryce, G; King-Robson, J; Simpson, JE; van der Pol, SMA; Hirst, MC; de Vries, HE; Sharrack, B;... (2015-03)

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS

Fox, RJ; Thompson, A; Baker, D; Baneke, P; Brown, D; Browne, P; Chandraratna, D; Ciccarelli, O; Coetzee, T; Comi, G;... (2012-11)

Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice

Peferoen, LAN; Breur, M; van de Berg, S; Peferoen-Baert, R; Boddeke, EHWGM; van der Valk, P; Pryce, G; van Noort, JM; Baker, D; Amor, S (2016-10)

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis

Al-Izki, S; Pryce, G; Hankey, DJR; Lidster, K; von Kutzleben, SM; Browne, L; Clutterbuck, L; Posada, C; Chan, AWE; Amor, S;... (2014-01)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Mao, Z; Álvarez-Gonzalez, C; De Trane, S; Yildiz, O; Albor, C; Doctor, G; Soon, D; Pepper, G; Turner, BP; Marta, M;... (2018-04)

Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...

Alemtuzumab depletion failure can occur in multiple sclerosis.

Dubuisson, N; Baker, D; Kang, AS; Pryce, G; Marta, M; Visser, LH; Hofmann, WE; Gnanapavan, S; Giovannoni, G; Schmierer, K (2018-06)

Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...

Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis

von Kutzleben, S; Pryce, G; Giovannoni, G; Baker, D (2017-04)

Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss.

Gushchina, S; Pryce, G; Yip, PK; Wu, D; Pallier, P; Giovannoni, G; Baker, D; Bo, X (2018-10)

Microglia contribute to pathophysiology at all stages of multiple sclerosis. Colony-stimulating factor-1 (CSF1) is crucial for microglial proliferation and activation. In this study we measured the CSF1 levels and studied ...

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis

Baker, D; Pryce, G; James, LK; Schmierer, K; Giovannoni, G (2020-02)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis

Afolabi, D; Albor, C; Zalewski, L; Altmann, DR; Baker, D; Schmierer, K (2018-10)